The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

Peer Review reports

Original Submission
10 Dec 2022	Submitted	Original manuscript
4 Jan 2023	Reviewed	Reviewer Report - Alexander Gough
8 Jan 2023	Reviewed	Reviewer Report - Singal AK
15 Feb 2023	Author responded	Author comments - Thomas Reiberger
Resubmission - Version 2
15 Feb 2023	Submitted	Manuscript version 2
17 Feb 2023	Reviewed	Reviewer Report - Alexander Gough
23 Feb 2023	Reviewed	Reviewer Report - Singal AK
8 Mar 2023	Author responded	Author comments - Thomas Reiberger
Resubmission - Version 3
8 Mar 2023	Submitted	Manuscript version 3
10 Mar 2023	Reviewed	Reviewer Report - Alexander Gough
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
3 Apr 2023	Editorially accepted
24 Apr 2023	Article published	10.1186/s13063-023-07291-3

Back to article page